# Eli Lilly (incl. Loxo)

Source: https://onco.cc/companies/eli-lilly/  
OnCo record `eli-lilly` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Eli Lilly makes Verzenio and Retevmo, as well as the oral SERD imlunestrant and the BTK inhibitor pirtobrutinib.

## Summary

Eli Lilly, based in Indianapolis and listed as LLY, makes Verzenio and Retevmo, the oral SERD imlunestrant and the BTK inhibitor pirtobrutinib, and its oncology unit includes Loxo Oncology. The portfolio spans abemaciclib, selpercatinib, imlunestrant, sold as Inluriyo from 2025, pirtobrutinib, olomorasib against KRAS G12C, a PI3K-alpha mutant-selective programme from Scorpion, and older products including cetuximab, gemcitabine and necitumumab. OnCo links it to the monarchE paper on two years of adjuvant abemaciclib, to CLEAR in kidney cancer, to GLP-1 receptor agonists and obesity-related cancer risk, to ideas for trials of GLP-1 drugs with cancer as the primary outcome, and to partners including Isomorphic Labs and Innovent. Whether Lilly's GLP-1 franchise becomes an oncology story is the question its idea links raise. Abemaciclib and selpercatinib have their own pages.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Indianapolis, IN
- Type: pharma
- Website: https://www.lilly.com
- Ticker: LLY

## Sources

- Official website: https://www.lilly.com

## Connected records

- fronts: [Hormonal Therapy](https://onco.cc/fronts/hormonal/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Imlunestrant](https://onco.cc/drugs/imlunestrant/), [Merestinib](https://onco.cc/drugs/merestinib/), [Nabilone](https://onco.cc/drugs/nabilone/), [Necitumumab](https://onco.cc/drugs/necitumumab/), [Olaratumab](https://onco.cc/drugs/olaratumab/), [Olomorasib](https://onco.cc/drugs/olomorasib/), [Pegilodecakin](https://onco.cc/drugs/pegilodecakin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Pirtobrutinib](https://onco.cc/drugs/pirtobrutinib/), [Raloxifene](https://onco.cc/drugs/raloxifene/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/), [Selpercatinib](https://onco.cc/drugs/selpercatinib/), [Sintilimab](https://onco.cc/drugs/sintilimab/), [Sofetabart Mipitecan](https://onco.cc/drugs/sofetabart-mipitecan/), [Tersolisib](https://onco.cc/drugs/tersolisib/), [Vepugratinib](https://onco.cc/drugs/vepugratinib/), [Vinblastine](https://onco.cc/drugs/vinblastine/), [Vincristine](https://onco.cc/drugs/vincristine/), [Vindesine](https://onco.cc/drugs/vindesine/)
- companies: [Emergence Therapeutics](https://onco.cc/companies/emergence-therapeutics/), [Innovent Biologics](https://onco.cc/companies/innovent/), [Isomorphic Labs](https://onco.cc/companies/isomorphic-labs/), [Kelonia Therapeutics](https://onco.cc/companies/kelonia-therapeutics/), [Lilly Ventures](https://onco.cc/companies/lilly-ventures/), [Mablink Bioscience](https://onco.cc/companies/mablink-bioscience/), [Orna Therapeutics (Eli Lilly)](https://onco.cc/companies/orna-therapeutics/), [POINT Biopharma](https://onco.cc/companies/point-biopharma/), [Scorpion Therapeutics](https://onco.cc/companies/scorpion-therapeutics/)
- trials: [A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer](https://onco.cc/trials/nct05999994/), [A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy](https://onco.cc/trials/nct06413706/), [A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://onco.cc/trials/nct06588478/), [A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer](https://onco.cc/trials/nct02107703/), [A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer](https://onco.cc/trials/nct02763566/), [A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer](https://onco.cc/trials/nct02152631/), [A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer](https://onco.cc/trials/nct02747004/), [A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)](https://onco.cc/trials/nct05288166/), [A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer](https://onco.cc/trials/nct03706365/), [A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer](https://onco.cc/trials/nct06119581/), [A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer](https://onco.cc/trials/nct07287098/), [A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer](https://onco.cc/trials/nct05514054/), [A Study of LY2784544 in Participants With Myeloproliferative Neoplasms](https://onco.cc/trials/nct01594723/), [A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation](https://onco.cc/trials/nct07814417/), [A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors](https://onco.cc/trials/nct03899792/), [A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)](https://onco.cc/trials/nct05023980/), [A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)](https://onco.cc/trials/nct05254743/), [A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE](https://onco.cc/trials/nct02411448/), [A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer](https://onco.cc/trials/nct02711553/), [A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET](https://onco.cc/trials/nct03157128/), [A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a](https://onco.cc/trials/nct04280081/), [A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct04819100/), [A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)](https://onco.cc/trials/pik3ca-2/), [A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract](https://onco.cc/trials/nct07218380/), [A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer](https://onco.cc/trials/nct07169851/), [A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer](https://onco.cc/trials/nct07213804/), [A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)](https://onco.cc/trials/nct04965493/), [ANNOUNCE](https://onco.cc/trials/announce/), [BRUIN CLL-321](https://onco.cc/trials/bruin-cll-321/), [CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma](https://onco.cc/trials/nct05440786/), [EMBER-3](https://onco.cc/trials/ember-3/), [First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05768139/), [LIBRETTO-431](https://onco.cc/trials/libretto-431/), [LIBRETTO-531](https://onco.cc/trials/libretto-531/), [Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers](https://onco.cc/trials/nct07162181/), [MONARCH 3](https://onco.cc/trials/monarch-3/), [monarchE](https://onco.cc/trials/monarche/), [postMONARCH](https://onco.cc/trials/postmonarch/), [RAINBOW](https://onco.cc/trials/rainbow/), [RAISE](https://onco.cc/trials/raise/), [REACH-2](https://onco.cc/trials/reach-2/), [REVEL](https://onco.cc/trials/revel/), [Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome](https://onco.cc/trials/nct04623541/), [SEQUOIA](https://onco.cc/trials/sequoia/), [SQUIRE](https://onco.cc/trials/squire/), [Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)](https://onco.cc/trials/nct04662255/), [Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)](https://onco.cc/trials/nct04956640/), [Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06890598/), [TAPUR (Targeted Agent and Profiling Utilization Registry)](https://onco.cc/trials/tapur/)
- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [KRAS G12C-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-g12c-pdac/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)](https://onco.cc/cancers/multiple-endocrine-neoplasia/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [RET fusion-positive non-small-cell lung cancer](https://onco.cc/cancers/ret-fusion-nsclc/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- ideas: [A trial of GLP-1 weight-loss drugs with cancer as the primary outcome](https://onco.cc/ideas/idea-prev-glp1-cancer-prevention-rct/), [GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer](https://onco.cc/ideas/idea-nl-glp1-adjuvant-hr-breast/)
- key papers: [CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer](https://onco.cc/key-papers/paper-clear-nejm-2021/), [monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-monarche-jco-2020/)
- technologies: [GLP-1 receptor agonists and obesity-related cancer risk](https://onco.cc/technologies/glp1-agonists-cancer-risk/)

---
JSON: https://onco.cc/api/v1/entities/eli-lilly.json